Serum Hepcidin-25 and All-Cause Mortality in Patients Undergoing Maintenance Hemodialysis

References

• STAFF N-KGD. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2(4):279–335.
   Google Scholar
• Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116(23):4754–4761. doi:10.1182/blood-2010-05-286260
   PubMed Web of Science ®Google Scholar
• Agarwal AK, Yee J. Hepcidin. Adv Chronic Kidney D. 2019;26(4):298–305. doi:10.1053/j.ackd.2019.04.005
   PubMed Web of Science ®Google Scholar
• Malyszko J, Malyszko JS, Matuszkiewicz-Rowinska J. Hepcidin as a therapeutic target for anemia and inflammation associated with chronic kidney disease. Expert Opin Ther Tar. 2019;23(5):407–421. doi:10.1080/14728222.2019.1599358
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Peng X, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. New Engl J Med. 2019;381(11):1001–1010. doi:10.1056/NEJMoa1813599
   PubMed Web of Science ®Google Scholar
• Chen N, Hao C, Liu BC, et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. New Engl J Med. 2019;381(11):1011–1022. doi:10.1056/NEJMoa1901713
   PubMed Web of Science ®Google Scholar
• Ueda N, Takasawa K. Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients. 2018;10(9):1173. doi:10.3390/nu10091173
   PubMed Web of Science ®Google Scholar
• Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292–4297. doi:10.1182/blood-2008-02-139915
   PubMed Web of Science ®Google Scholar
• Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation?: differential diagnosis and mechanisms of anemia of inflammation. Wien Med Wochenschr. 2016;166(13–14):411–423. doi:10.1007/s10354-016-0505-7
   PubMed Web of Science ®Google Scholar
• Ueda N, Takasawa K. Role of Hepcidin-25 in Chronic Kidney Disease: anemia and Beyond. Curr Med Chem. 2017;24(14):1417–1452. doi:10.2174/0929867324666170316120538
   PubMed Web of Science ®Google Scholar
• Alaaddin K, Ozlem Y, Bulent E, et al. Is hepcidin-25 a predictor of atherosclerosis in hemodialysis patients? Hemodial Int. 2016;20:191–197. doi:10.1111/hdi.12355
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang Y, Hu H, Li J, Tian T. Relationship between serum hepcidin levels and cardiovascular disease in patients with maintenance hemodialysis. Physiol Int. 2020;107(4):491–500. doi:10.1556/2060.2020.00040
   PubMed Web of Science ®Google Scholar
• Tessitore N, Girelli D, Campostrini N, et al. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents. Nephrol Dial Transplant. 2010;25(12):3996–4002. doi:10.1093/ndt/gfq321
   PubMed Web of Science ®Google Scholar
• Gaillard CA, Bock AH, Carrera F, et al. Hepcidin response to iron therapy in patients with non-dialysis dependent CKD: an analysis of the FIND-CKD trial. PLoS One. 2016;11(6):e0157063. doi:10.1371/journal.pone.0157063
   PubMed Web of Science ®Google Scholar
• Petruliene K, Ziginskiene E, Kuzminskis V, Nedzelskiene I, Bumblyte IA. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Medicina (Kaunas). 2017;53(2):90–100. doi:10.1016/j.medici.2017.03.001
   PubMed Web of Science ®Google Scholar
• Daugirdas JT. Kt/V (and especially its modifications) remains a useful measure of hemodialysis dose. Kidney Int. 2015;88(3):466–473. doi:10.1038/ki.2015.204
   PubMed Web of Science ®Google Scholar
• Suttorp MM, Hoekstra T, Rotmans JI, et al. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol. 2013;14:200. doi:10.1186/1471-2369-14-200
   PubMed Web of Science ®Google Scholar
• Busbridge M, Griffiths C, Ashby D, et al. Development of a novel immunoassay for the iron regulatory peptide hepcidin. Br J Biomed Sci. 2009;66(3):150–157. doi:10.1080/09674845.2009.11730263
   PubMed Web of Science ®Google Scholar
• Reshef DN, Reshef YA, Finucane HK, et al. Detecting Novel associations in large datasets. Science. 2011;334(6062):1518–1524. doi:10.1126/science.1205438
   PubMed Web of Science ®Google Scholar
• Slotki I, Cabantchik ZI. The labile side of iron supplementation in CKD. J Am Soc Nephrol. 2015;26(11):2612–2619. doi:10.1681/ASN.2015010052
   PubMed Web of Science ®Google Scholar
• Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol. 2017;18(1):345. doi:10.1186/s12882-017-0688-1
   PubMed Web of Science ®Google Scholar
• Wojtaszek E, Glogowski T, Malyszko J. Iron and chronic kidney disease: still a challenge. Front Med (Lausanne). 2020;7:565135. doi:10.3389/fmed.2020.565135
   PubMed Web of Science ®Google Scholar
• Lee SW, Kim YH, Chung W, et al. Serum hepcidin and iron indices affect anemia status differently according to the kidney function of non-dialysis chronic kidney disease patients: korean Cohort Study For Outcome in Patients with Chronic Kidney Disease (KNOW-CKD). Kidney Blood Press Res. 2017;42(6):1183–1192. doi:10.1159/000485865
   PubMed Web of Science ®Google Scholar
• Gaweda AE. Markers of iron status in chronic kidney disease. Hemodial Int. 2017;21(Suppl 1):S21–S27. doi:10.1111/hdi.12556
   PubMed Web of Science ®Google Scholar
• Ogawa C, Tsuchiya K, Tomosugi N, Kanda F, Maeda K, Maeda T. Low levels of serum ferritin and moderate transferrin saturation lead to adequate hemoglobin levels in hemodialysis patients, retrospective observational study. PLoS One. 2017;12(6):e0179608. doi:10.1371/journal.pone.0179608
   PubMed Web of Science ®Google Scholar
• Wei Y, Zhou J, Zhang Z, et al. Application of restricted cube spline in cox regression model. Zhonghua Yufang Yixue Zazhi. 2020;54(10):1169–1173. doi:10.3760/cma.j.cn112150-20200804-01092
   PubMedGoogle Scholar